Copyright Reports & Markets. All rights reserved.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption 2014-2024
        • 2.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption CAGR by Region
      • 2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
        • 2.2.1 Calcium Channel α2-delta Ligands
        • 2.2.2 Antidepressants
        • 2.2.3 Opioids
        • 2.2.4 Others
      • 2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
        • 2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Type (2014-2019)
      • 2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
        • 2.4.1 Platinum Agents
        • 2.4.2 Taxanes
        • 2.4.3 Vinca Alkaloids
        • 2.4.4 Others
      • 2.5 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
        • 2.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Application (2014-2019)

      3 Global Chemotherapy Induced Peripheral Neuropathy Treatment by Players

      • 3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Players
        • 3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Players (2017-2019)
        • 3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Players (2017-2019)
      • 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Players
        • 3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Players (2017-2019)
        • 3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Players (2017-2019)
      • 3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Players
      • 3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Chemotherapy Induced Peripheral Neuropathy Treatment by Regions

      • 4.1 Chemotherapy Induced Peripheral Neuropathy Treatment by Regions
        • 4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Regions
        • 4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Value by Regions
      • 4.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
      • 4.3 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
      • 4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
      • 4.5 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth

      5 Americas

      • 5.1 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries
        • 5.1.1 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2014-2019)
        • 5.1.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2014-2019)
      • 5.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
      • 5.3 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries
        • 6.1.1 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2014-2019)
        • 6.1.2 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2014-2019)
      • 6.2 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
      • 6.3 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
        • 7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2014-2019)
        • 7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2014-2019)
      • 7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
      • 7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
        • 8.1.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
      • 8.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
      • 10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customer

      11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast

      • 11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2019-2024)
      • 11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Regions
        • 11.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Regions (2019-2024)
        • 11.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Type
      • 11.8 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Application

      12 Key Players Analysis

      • 12.1 Aptinyx
        • 12.1.1 Company Details
        • 12.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.1.3 Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Aptinyx News
      • 12.2 Asahi Kasei Pharma
        • 12.2.1 Company Details
        • 12.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.2.3 Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Asahi Kasei Pharma News
      • 12.3 Regenacy Pharmaceuticals
        • 12.3.1 Company Details
        • 12.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Regenacy Pharmaceuticals News
      • 12.4 MAKScientific
        • 12.4.1 Company Details
        • 12.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.4.3 MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 MAKScientific News
      • 12.5 Metys Pharmaceuticals
        • 12.5.1 Company Details
        • 12.5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.5.3 Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Metys Pharmaceuticals News
      • 12.6 Nemus Bioscience
        • 12.6.1 Company Details
        • 12.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.6.3 Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 Nemus Bioscience News
      • 12.7 PledPharma
        • 12.7.1 Company Details
        • 12.7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 PledPharma News
      • 12.8 Sova Pharmaceuticals
        • 12.8.1 Company Details
        • 12.8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.8.3 Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 Sova Pharmaceuticals News
      • 12.9 DermaXon
        • 12.9.1 Company Details
        • 12.9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.9.3 DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.9.4 Main Business Overview
        • 12.9.5 DermaXon News
      • 12.10 Immune Pharmaceuticals
        • 12.10.1 Company Details
        • 12.10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
        • 12.10.3 Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.10.4 Main Business Overview
        • 12.10.5 Immune Pharmaceuticals News
      • 12.11 Kineta
      • 12.12 Krenitsky Pharmaceuticals
      • 12.13 PeriphaGen
      • 12.14 Apexian Pharma
      • 12.15 WinSanTor
      • 12.16 Solasia Pharma

      13 Research Findings and Conclusion

      CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
      The classification of Chemotherapy Induced Peripheral Neuropathy Treatment includes Calcium channel α2-delta ligands, Antidepressants, Opioids and Other Drugs. And the proportion of Opioids in 2017 is about 27%, and the proportion is in decreasing trend from 2013 to 2017.
      Chemotherapy Induced Peripheral Neuropathy Treatment is widely used for CIPN cause by Platinum Agents, Taxanes, Vinca Alkaloids and Others. The most proportion of Chemotherapy Induced Peripheral Neuropathy Treatment is used in Platinum Agents, and the proportion in 2017 is 42%.
      North America is the largest sales place, with a sales market share nearly 41% in 2017. Following North America, Europe is the second largest sales place with the sales market share of 27%.

      According to this study, over the next five years the Chemotherapy Induced Peripheral Neuropathy Treatment market will register a 6.4% CAGR in terms of revenue, the global market size will reach US$ 1880 million by 2024, from US$ 1300 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Peripheral Neuropathy Treatment business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Peripheral Neuropathy Treatment market by product type, application, key manufacturers and key regions and countries.

      This study considers the Chemotherapy Induced Peripheral Neuropathy Treatment value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Calcium Channel α2-delta Ligands
      Antidepressants
      Opioids
      Others
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Platinum Agents
      Taxanes
      Vinca Alkaloids
      Others

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Aptinyx
      Asahi Kasei Pharma
      Regenacy Pharmaceuticals
      MAKScientific
      Metys Pharmaceuticals
      Nemus Bioscience
      PledPharma
      Sova Pharmaceuticals
      DermaXon
      Immune Pharmaceuticals
      Kineta
      Krenitsky Pharmaceuticals
      PeriphaGen
      Apexian Pharma
      WinSanTor
      Solasia Pharma

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Chemotherapy Induced Peripheral Neuropathy Treatment consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Chemotherapy Induced Peripheral Neuropathy Treatment market by identifying its various subsegments.
      Focuses on the key global Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Chemotherapy Induced Peripheral Neuropathy Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Chemotherapy Induced Peripheral Neuropathy Treatment submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now